This annual report includes patients with prostate cancer from 2004 to 2022. The reference group for the Norwe- gian Prostate Cancer Registry has defined quality indicators relevant for this group of patients accompanied by target levels of achievement. See table 1.1 for an overview of general results and results for the national quality indicators.
Five of the quality indicators established in 2018 have been kept in the 2022 report and one new has been added. Overall, the quality of prostate cancer treatment and diagnostic is good, and it seems that norwegian men gets equal care across the country. A report like this will always be affected by natural variation in the patient population, and may not indicate differences in practice. However we hope the departments will evaluate their own results more in dept, to see if their own practice should be improved or changed.
The report also includes results on patient reported outcome measures (PROM) and patient reported experience measures (PREM) (chapter 3.7 and 3.7.2).
For the first time the report presents results about medical treatment (chemotherapy and antihormonal treatment) for patients with metastatic prostate cancer at the time of diagnosis, and overall medical treatment the last three months before death.
